| URN | urn:agi-llid:4846 |
|---|---|
| Total Entities | 0 |
| Connectivity | 4455 |
| Name | Nos3 |
| Description | nitric oxide synthase 3 (endothelial cell) |
| Notes | Nitric oxide is a reactive free radical which acts as a biologic mediator in several processes, including neurotransmission and antimicrobial and antitumoral activities. Nitric oxide is synthesized from L-arginine by nitric oxide synthases. Variations in this gene are associated with susceptibility to coronary spasm. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009] |
| GO Molecular Function | oxidoreductase activity |
|---|---|
| nitric-oxide synthase activity | |
| NADPH-hemoprotein reductase activity | |
| calmodulin binding | |
| beta-catenin binding | |
| nitric-oxide synthase binding | |
| actin binding | |
| actin monomer binding | |
| Hsp90 protein binding | |
| cadherin binding | |
| flavin adenine dinucleotide binding | |
| NADP binding | |
| FMN binding | |
| arginine binding | |
| tetrahydrobiopterin binding | |
| heme binding | |
| metal ion binding | |
| iron ion binding | |
| cadmium ion binding |
| GO Cellular Component | membrane |
|---|---|
| caveola | |
| vesicle membrane | |
| endocytic vesicle membrane | |
| Golgi membrane | |
| nucleolus | |
| plasma membrane | |
| apical part of cell | |
| cytoplasm | |
| Golgi apparatus | |
| cytosol | |
| mitochondrion | |
| cytoskeleton | |
| nucleus | |
| sarcolemma |
| GO Biological Process | ovulation from ovarian follicle |
|---|---|
| female pregnancy | |
| small molecule metabolic process | |
| oxidation-reduction process | |
| positive regulation of guanylate cyclase activity | |
| arginine catabolic process | |
| regulation of nitric-oxide synthase activity | |
| positive regulation of vasodilation | |
| negative regulation of muscle hyperplasia | |
| negative regulation of platelet activation | |
| blood vessel remodeling | |
| blood coagulation | |
| regulation of systemic arterial blood pressure by endothelin | |
| smooth muscle hyperplasia | |
| regulation of blood vessel size | |
| regulation of the force of heart contraction by chemical signal | |
| regulation of blood pressure | |
| negative regulation of blood pressure | |
| angiogenesis | |
| positive regulation of angiogenesis | |
| lung development | |
| retina development in camera-type eye | |
| in utero embryonic development | |
| endothelial cell migration | |
| aging | |
| signal transduction | |
| nitric oxide mediated signal transduction | |
| negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | |
| lipopolysaccharide-mediated signaling pathway | |
| positive regulation of apoptotic process | |
| negative regulation of cell proliferation | |
| negative regulation of smooth muscle cell proliferation | |
| regulation of sodium ion transport | |
| negative regulation of calcium ion transport | |
| negative regulation of potassium ion transport | |
| response to activity | |
| response to drug | |
| response to salt | |
| response to amino acid | |
| response to candesartan | |
| response to peptide | |
| response to lipopolysaccharide | |
| response to fructose | |
| response to estradiol | |
| response to ethanol | |
| response to peptide hormone | |
| response to lead ion | |
| cellular response to organic cyclic compound | |
| cellular response to transforming growth factor beta stimulus | |
| response to cytokine | |
| response to lipoprotein particle | |
| response to organic cyclic compound | |
| response to hypoxia | |
| response to fluid shear stress | |
| response to hyperoxia | |
| response to heat | |
| response to axon injury | |
| cellular response to heat | |
| response to mechanical stimulus | |
| cellular response to mechanical stimulus | |
| negative regulation of hydrolase activity | |
| nitric oxide biosynthetic process | |
| nitric oxide metabolic process | |
| mitochondrion organization | |
| phagosome maturation | |
| interaction with host |
| Pathway | Transcytosis |
|---|---|
| Proteins Involved in Pathogenesis of Alzheimer's Disease | |
| Activation of eNOS (NOS3) via Prostaglandin E2 and Histamine in Familial Hemiplegic Migraine | |
| Proliferative Diabetic Retinopathy | |
| Proteins Involved in Pathogenesis of Insulin Resistance | |
| Role of Adiponectin in Insulin Resistance Prevention | |
| Proteins Involved in Pathogenesis of Diabetes Mellitus Type 2 | |
| Peripheral Tissue Microangiopathy in Insulin Resistance | |
| Proteins Involved in Pathogenesis of Vasospasm | |
| NO Synthesis in Early Vasospasm | |
| CFTR-Related Ion-Channel Dysfunction in Cystic Fibrosis Airway Epithelium (Class III Mutations) | |
| Proteins Involved in Pathogenesis of Atherosclerosis | |
| Endothelial Cell Dysfunction in Pulmonary Arterial Hypertension | |
| Hemolysis-Associated Arterial Pulmonary Hypertension | |
| Proteins Involved in Pathogenesis of Pulmonary Hypertension | |
| Proteins Involved in Pathogenesis of Hypoxia-Induced Pulmonary Hypertension | |
| Proteins Involved in Pathogenesis of Astrocytoma | |
| Proteins Involved in Pathogenesis of Hepatocellular Carcinoma | |
| Proteins Involved in Pathogenesis of Raynaud Disease | |
| NO and ADMA Signaling in Raynaud Disease | |
| Regulation of Vascular Reactivity in Raynaud Disease | |
| Proteins Involved in Pathogenesis of Myocardial Ischemia | |
| Preconditioning Ischemia | |
| Role of Scavenger Receptor OLR1 in Inflammation-Related Endothelial Dysfunction in Atherosclerosis | |
| ADRB1/3 -> vasodilation | |
| BDKRB1/2 -> vasodilation | |
| HRH1/2 -> vascular motility | |
| PTGDR -> vasodilation | |
| PTGER1/4 -> vascular motility | |
| PTGER2/3 -> vascular motility | |
| PTGIR -> vasodilation | |
| HTR1 -> vascular motility | |
| HTR4/6/7 -> vasodilation | |
| CNR1/2 -> vascular motility | |
| EDNRA/B -> vascular motility | |
| CHRM1/2/3 -> vascular motility | |
| Leptin -> NO production/vasodilation | |
| Nociception-related IL6 expression targets | |
| Summarized vascular motility pathway | |
| Ritonavir-Induced Cardiovascular Dysfunction | |
| ROS and RNS in the Regulation of Vasoconstriction and Vasodilation | |
| FASLG Expression Targets | |
| NGF/FOXO/MYCN/ELK-SRF Expression Targets | |
| TNF/TP53/ATF Expression Targets | |
| NGF/SMAD3/NF-kB Expression Targets | |
| IL10 Expression Targets | |
| Erythropoietin/NF-kB Expression Targets | |
| GH1-GHR/NF-kB/ELK-SRF/MYC Expression Targets | |
| GH1-GHR/STAT Expression Targets | |
| CSF3 Expression Targets | |
| CSF2/NF-kB Expression Targets | |
| Leptin/ELK-SRF Expression Targets | |
| Leptin/STAT Expression Targets | |
| SST Expression Targets | |
| EGF/TP53 Expression Targets | |
| VEGFC/ATF Expression Target | |
| Erythropoietin/FOXO3A Expression Targets | |
| EGF/FOXO3A Expression Targets | |
| FGF2/FOXO3A Expression Targets | |
| VEGFA/FOXO3A Expression Targets | |
| F2 -> AP-1/CREB/ELK-SRF/SP1 Expression Targets | |
| F2 -> STAT1/NF-kB Expression Targets | |
| Adenosine Expression Targets | |
| AVP/Gq -> MEF/MYOD/NFATC/MYOG Expression Targets | |
| IFNA1/Gq Expression Targets | |
| AGT/TP53 Expression Targets | |
| FGF2/AP-1/CREB/CREBBP/ELK-SRF/MYC Expression Targets | |
| IGF1/CEBPA/FOXO1A Expression Targets | |
| IGF1/STAT Expression Targets | |
| Insulin/ELK-SRF/HIF1A/MYC/SREBF Expression Targets | |
| Insulin/STAT Expression Targets | |
| TCR/NF-kB Expression Targets | |
| FGF2/STAT Expression Targets | |
| TGFB1-TGFBR1 Expression Targets | |
| EGF/AP-1/ATF Expression Targets | |
| EGF/CREB/CREBBP/ELK-SRF/MYC Expression Targets | |
| EGF/MEF/MYOD/NFATC Expression Targets | |
| EGF/STAT Expression Targets | |
| IGF1/ELK-SRF/HIF1A/MYC/SREBF Expression Targets | |
| IGF1/MEF/MYOD/MYOG Expression Targets | |
| Insulin/CEBPA/CTNNB/FOXA/FOXO Expression Targets | |
| Insulin/MEF/MYOD Expression Targets | |
| TGFB1-ACVRL1 Expression Targets | |
| EGF/CTNN Expression Targets | |
| doxorubicin pharmacokinetics pathway |
| Group | NO biosyntheis |
|---|---|
| NOS | |
| ovulation from ovarian follicle | |
| female pregnancy | |
| small molecule metabolic process | |
| oxidation-reduction process | |
| positive regulation of guanylate cyclase activity | |
| arginine catabolic process | |
| oxidoreductase activity | |
| nitric-oxide synthase activity | |
| regulation of nitric-oxide synthase activity | |
| NADPH-hemoprotein reductase activity | |
| positive regulation of vasodilation | |
| negative regulation of muscle hyperplasia | |
| negative regulation of platelet activation | |
| blood vessel remodeling | |
| blood coagulation | |
| regulation of systemic arterial blood pressure by endothelin | |
| smooth muscle hyperplasia | |
| regulation of blood vessel size | |
| regulation of the force of heart contraction by chemical signal | |
| regulation of blood pressure | |
| negative regulation of blood pressure | |
| angiogenesis | |
| positive regulation of angiogenesis | |
| lung development | |
| retina development in camera-type eye | |
| in utero embryonic development | |
| endothelial cell migration | |
| aging | |
| signal transduction | |
| nitric oxide mediated signal transduction | |
| negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | |
| lipopolysaccharide-mediated signaling pathway | |
| positive regulation of apoptotic process | |
| negative regulation of cell proliferation | |
| negative regulation of smooth muscle cell proliferation | |
| regulation of sodium ion transport | |
| negative regulation of calcium ion transport | |
| negative regulation of potassium ion transport | |
| response to activity | |
| response to drug | |
| response to salt | |
| response to amino acid | |
| response to candesartan | |
| response to peptide | |
| response to lipopolysaccharide | |
| response to fructose | |
| response to estradiol | |
| response to ethanol | |
| response to peptide hormone | |
| response to lead ion | |
| cellular response to organic cyclic compound | |
| cellular response to transforming growth factor beta stimulus | |
| response to cytokine | |
| response to lipoprotein particle | |
| response to organic cyclic compound | |
| response to hypoxia | |
| response to fluid shear stress | |
| response to hyperoxia | |
| response to heat | |
| response to axon injury | |
| cellular response to heat | |
| response to mechanical stimulus | |
| cellular response to mechanical stimulus | |
| negative regulation of hydrolase activity | |
| nitric oxide biosynthetic process | |
| nitric oxide metabolic process | |
| mitochondrion organization | |
| phagosome maturation | |
| interaction with host | |
| calmodulin binding | |
| beta-catenin binding | |
| nitric-oxide synthase binding | |
| actin binding | |
| actin monomer binding | |
| Hsp90 protein binding | |
| cadherin binding | |
| flavin adenine dinucleotide binding | |
| NADP binding | |
| FMN binding | |
| arginine binding | |
| tetrahydrobiopterin binding | |
| heme binding | |
| metal ion binding | |
| iron ion binding | |
| cadmium ion binding | |
| membrane | |
| caveola | |
| vesicle membrane | |
| endocytic vesicle membrane | |
| Golgi membrane | |
| nucleolus | |
| plasma membrane | |
| apical part of cell | |
| cytoplasm | |
| Golgi apparatus | |
| cytosol | |
| mitochondrion | |
| cytoskeleton | |
| nucleus | |
| sarcolemma | |
| Genes Associated with Systemic Lupus Erythematosus | |
| Genes with Mutations Associated with Systemic Scleroderma | |
| Genes with Mutations Associated with Atherosclerosis | |
| Secreted proteins | |
| Biofluids assayable substances |
| LocusLink ID | 4846 |
|---|---|
| 18127 | |
| 24600 |
| Cell Localization | Cytoplasm |
|---|---|
| Membrane | |
| Caveola | |
| Cytoskeleton | |
| Golgi apparatus | |
| Cell membrane |
| GO ID | 0010181 |
|---|---|
| 0050661 | |
| 0003958 | |
| 0003785 | |
| 0034618 | |
| 0046870 | |
| 0005516 | |
| 0050660 | |
| 0020037 | |
| 0005506 | |
| 0004517 | |
| 0034617 | |
| 0001525 | |
| 0006527 | |
| 0007596 | |
| 0001974 | |
| 0043542 | |
| 0001701 | |
| 0051701 | |
| 0031663 | |
| 0030324 | |
| 0007005 | |
| 0045776 | |
| 0051926 | |
| 0008285 | |
| 1902042 | |
| 0051346 | |
| 0014740 | |
| 0010544 | |
| 0043267 | |
| 0006809 | |
| 0007263 | |
| 0046209 | |
| 0001542 | |
| 0090382 | |
| 0045766 | |
| 0031284 | |
| 0045909 | |
| 0008217 | |
| 0050880 | |
| 0050999 | |
| 0002028 | |
| 0003100 | |
| 0003057 | |
| 0034405 | |
| 0009408 | |
| 0044281 | |
| 0014806 | |
| 0000139 | |
| 0005901 | |
| 0005737 | |
| 0005856 | |
| 0005829 | |
| 0030666 | |
| 0005634 | |
| 0005886 | |
| 0051879 | |
| 0046872 | |
| 0016491 | |
| 0071260 | |
| 0071560 | |
| 0048662 | |
| 0055114 | |
| 0043065 | |
| 0032355 | |
| 0007165 | |
| 0005794 | |
| 0045177 | |
| 0016020 | |
| 0005739 | |
| 0005730 | |
| 0012506 | |
| 0003779 | |
| 0008013 | |
| 0045296 | |
| 0050998 | |
| 0007568 | |
| 0034605 | |
| 0071407 | |
| 0007565 | |
| 0014823 | |
| 0043200 | |
| 0048678 | |
| 1901556 | |
| 0034097 | |
| 0042493 | |
| 0045471 | |
| 0009750 | |
| 0055093 | |
| 0001666 | |
| 0010288 | |
| 0032496 | |
| 0055094 | |
| 0009612 | |
| 0014070 | |
| 1901652 | |
| 0043434 | |
| 1902074 | |
| 0060041 | |
| 0042383 |
| Alias | eNOS |
|---|---|
| ECNOS | |
| nitric oxide synthase, endothelial | |
| cNOS | |
| EC-NOS | |
| NOSIII | |
| NOS type III | |
| endothelial NOS | |
| constitutive NOS | |
| nitric oxide synthase 3 transcript variant eNOS-delta20 | |
| nitric oxide synthase 3 transcript variant eNOS-delta21 | |
| nitric oxide synthase 3 transcript variant eNOS-delta20-21 | |
| Nos-3 | |
| 2310065A03Rik | |
| endothelial nitric oxide synthase | |
| endothelial nitric oxide synthase 3 | |
| nitric oxide synthetase 3 (endothelial cell) | |
| NO synthase III | |
| NO synthase 3 | |
| Nitric-oxide synthetase, endothelial | |
| Nitric-oxide synthase, endothelial | |
| NO synthetase 3 | |
| nitric oxide synthetase 3-like | |
| nitric oxide synthetase 3 | |
| nitric oxide synthase III | |
| nitric oxide synthase 3-like | |
| nitric oxide synthetase III | |
| NO synthetase III | |
| NOS3L | |
| OTTHUMP00000213183 | |
| OTTMUSP00000028591 | |
| OTTMUSP00000028592 | |
| RIKEN cDNA 2310065A03 gene | |
| nitric oxide synthase 3 (endothelial cell) | |
| NOS3 | |
| nitric oxide synthase 3 | |
| 2310065A03 | |
| endothelial nitric oxidase synthase | |
| endothelial nitric oxidase synthetase | |
| Endothelial nitric oxide synthase III | |
| endothelial nitric oxide synthetase | |
| Endothelial NO synthetase III | |
| Endothelial nitric oxide synthetase 3 | |
| Endothelial NO synthetase 3 | |
| endothelial NO synthetase | |
| Endothelial NO synthase III | |
| Endothelial NO synthase 3 | |
| endothelial NO synthase | |
| Endothelial nitric oxide synthetase III |
| Mouse chromosome position | 5 11.32 cM |
|---|
| OMIM ID | 163729 |
|---|---|
| 104300 | |
| 145500 | |
| 601367 | |
| 189800 |
| Rat chromosome position | 4q11 |
|---|
| Hugo ID | 7876 |
|---|
| Human chromosome position | 7q36 |
|---|
| Swiss-Prot Accession | P29474 |
|---|---|
| A0S0A6 | |
| P70313 | |
| Q8C5P3 | |
| Q62600 | |
| O55056 | |
| Q7TSV7 | |
| A0S0A7 | |
| A0S0A8 | |
| A8KA63 | |
| B2RCQ1 | |
| E9PFR2 | |
| Q13662 | |
| Q14251 | |
| Q14434 | |
| Q548C1 | |
| Q6GSL5 | |
| Q9UDC6 | |
| O88672 | |
| O89041 | |
| Q62734 | |
| Q68GV6 | |
| Q75NE4 |
| PIR ID | S71424 |
|---|---|
| A47501 | |
| I51917 | |
| I56979 |
| Unigene ID | Hs.647092 |
|---|---|
| Mm.258415 | |
| Rn.44265 |
| KEGG ID | hsa:4846 |
|---|---|
| mmu:18127 | |
| rno:24600 |
| Swiss-Prot ID | NOS3_MOUSE |
|---|---|
| NOS3_HUMAN | |
| NOS3_RAT |
| EC Number | 1.14.13.39 |
|---|
| Ensembl ID | ENSG00000164867 |
|---|---|
| ENSP00000297494 | |
| ENST00000297494 | |
| ENSP00000420551 | |
| ENST00000467517 | |
| ENSP00000420215 | |
| ENST00000484524 | |
| ENSMUSG00000028978 | |
| ENSMUSP00000030834 | |
| ENSMUST00000030834 | |
| ENSRNOG00000009348 | |
| ENSRNOP00000013058 | |
| ENSRNOT00000013058 |
| Homologene ID | 504 |
|---|
| Organism | Homo sapiens |
|---|---|
| Mus musculus | |
| Rattus norvegicus |
| MGI ID | 97362 |
|---|
| RGD ID | 3186 |
|---|
| MedScan ID | 4846 |
|---|